File this under, “It’s the fees, stupid!”

At a time when rebates are increasingly blamed for rising medicine costs, another type of behind-the-scenes payment in the pharmaceutical supply chain is being cited as an explanation for high drug prices — the various fees that pharmacy benefit managers charge drug makers.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Fairness and justice in the drug industry move techtonically slow. (Picture a turtle climbing Mount Everest). I hope to live and see the day when the PBMs finally get their comeuppance, but at age 58, I doubt I’ll live that long.

    Expect the PBMs to go full Gotti to prevent the green curtain from opening.

    • You are so right Corey…. We will never see the PBM’s sleep with the fish as they say in my neighborhood. I guess the federal government wants to see the Independent Pharmacy become extinct. I was talking to a friend of mine who owns 4 pharmacies in the NYC area. He’s also past president of PSSNY (pharmacy society state of NY), we both agree , between the PBM’s paying us below our cost of medications and these d.i.r fees , we will ALL be out of business within 6 months. This can’t continue like this and stay in business.
      This is a pattern of criminal activity that a first year law student would classify as a classic RICCO case against the PBM’s. The PBM’s are diverting the problem of high price of medication on to the manufacturer. The problem is the PBM’s and their greed.
      I’m on the front lines of this battle , I live this PBM greed every day.
      Let me talk to Alex Azar for 10 minutes and I can show him where the billions are going….
      In the PBM’s pockets.

  • RE: ‘Consumers deserve to know more…’
    You bet.
    But drugs and devices are not the only gov regulated business
    where the real negotiations take place behind closed doors.
    Trust your legislators?
    Or implement more independent oversight, e.g. GAO scrutiny.

  • Probably a relatively small factor, of many cost factors,
    but very unwelcome new publicity for PBMs, which are
    already being spotlighted as suspected bad players.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy